Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.

A new light-based imaging approach has produced an unprecedented chemical map of the Alzheimer’s brain. Rice University researchers have produced what they describe as the first full, label-free ...

Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. | A new entrant in the race to shepherd antibodies for Alzheimer’s disease across ...

Add Yahoo as a preferred source to see more of our stories on Google. An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to ...

Researchers used CAR T therapy to target beta amyloid plaques in Alzheimer’s disease. In mice, the modified immune cells ...

A new study study finds that brain swelling (ARIA-E) from Alzheimer's drugs identifies the regions where amyloid plaques are being cleared most effectively.

Researchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimer’s ...

Researchers at Niigata University have used advanced three-dimensional (3D) imaging to reveal how amyloid β (Aβ) deposits ...

Scientists have repaired a natural gateway into the brains of mice, allowing the clumps and tangles associated with Alzheimer's disease to be swept away. After just three drug injections, mice with ...